Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BACKGROUND: Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties. METHODS: This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75...

Descripción completa

Detalles Bibliográficos
Autores principales: Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731782/
https://www.ncbi.nlm.nih.gov/pubmed/19643020
http://dx.doi.org/10.1186/1471-2407-9-263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731782/
https://www.ncbi.nlm.nih.gov/pubmed/19643020
http://dx.doi.org/10.1186/1471-2407-9-263

Ejemplares similares